Pancreaticoduodenectomy at a Non-high-volume Center and Efforts to Perform Safe Surgery.
Adult
Aged
Aged, 80 and over
Anastomosis, Surgical
/ standards
Blood Loss, Surgical
/ prevention & control
Female
Follow-Up Studies
Hospitals, High-Volume
/ standards
Humans
Male
Middle Aged
Pancreatic Neoplasms
/ pathology
Pancreaticoduodenectomy
/ standards
Postoperative Complications
/ prevention & control
Prognosis
Retrospective Studies
Survival Rate
Pancreaticoduodenectomy
artery-first approach
non-high volume center
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
16
06
2021
revised:
15
08
2021
accepted:
24
08
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
12
10
2021
Statut:
ppublish
Résumé
The aim of the current study was to investigate whether the artery-first approach (AFA) improved surgical outcomes of pancreaticoduodenectomy (PD) at our non-high-volume center. We retrospectively reviewed data on 121 consecutive patients who underwent PD between January 2009 and December 2018. The perioperative data of 49 patients who underwent conventional PD (conventional group) and 72 patients who underwent PD via artery-first approach were analyzed and compared to assess the effectiveness of the AFA. Although no significant difference was observed between the two groups overall, in those with pancreatic cancer, the duration of surgery, intraoperative blood loss and transfusion rate in the AFA group (n=33) were significantly lower than those for the conventional group (n=11) (p=0.011, p=0.021 and p=0.038 respectively). AFA can be used to reduce the operative time, intraoperative blood loss, and transfusion rate in patients with pancreatic cancer.
Identifiants
pubmed: 34593475
pii: 41/10/5223
doi: 10.21873/anticanres.15341
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5223-5229Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.